Miki Horiguchi
Overview
Explore the profile of Miki Horiguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biller L, Mittendorf K, Horiguchi M, Caruso A, Chittenden A, Ukaegbu C, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2500058.
PMID: 39991988
No abstract available.
2.
Biller L, Mittendorf K, Horiguchi M, Caruso A, Chittenden A, Ukaegbu C, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400691.
PMID: 39772830
Purpose: Clinical risk assessment models can identify patients with hereditary cancer susceptibility, but it is unknown how multigene cancer syndrome prediction models compare with syndrome-specific models in assessing risk for...
3.
Geiger G, Revette A, Nava-Coulter B, Kiel L, Kaufman R, Morabito A, et al.
Cancer
. 2025 Jan;
131(1):e35700.
PMID: 39748490
Background: Despite increased recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique retentive barriers affecting this population. Discriminatory experiences involving bias may contribute to...
4.
Uno H, Horiguchi M
JCO Precis Oncol
. 2024 Jul;
8:e2400358.
PMID: 39038245
Biomarker-driven trials are key for precision oncology but challenge design and analysis.
5.
Shi Y, Horiguchi M, Lu Y
JCO Precis Oncol
. 2024 May;
8:e2400220.
PMID: 38781547
No abstract available.
6.
Uno H, Tian L, Horiguchi M, Hattori S, Kehl K
Biometrics
. 2024 May;
80(2).
PMID: 38771658
Limitations of using the traditional Cox's hazard ratio for summarizing the magnitude of the treatment effect on time-to-event outcomes have been widely discussed, and alternative measures that do not have...
7.
Rodriguez N, Furniss C, Yurgelun M, Ukaegbu C, Constantinou P, Fortes I, et al.
Gastroenterology
. 2024 Feb;
166(5):872-885.e2.
PMID: 38320723
Background & Aims: Genetic testing uptake for cancer susceptibility in family members of patients with cancer is suboptimal. Among relatives of patients with pancreatic ductal adenocarcinoma (PDAC), The GENetic Education,...
8.
Geiger G, Kiel L, Horiguchi M, Martinez-Aceves C, Meza K, Christophers B, et al.
BMC Med Educ
. 2024 Jan;
24(1):4.
PMID: 38172800
Background: The percentage of physicians identifying as Latina has not improved despite improvements in recruitment of Latina medical students, suggesting barriers to retention and career advancement. Discriminatory experiences and mental...
9.
Sandoval R, Horiguchi M, Ukaegbu C, Furniss C, Uno H, Syngal S, et al.
Fam Cancer
. 2023 Aug;
22(4):459-465.
PMID: 37572151
Current algorithms for diagnosing Lynch syndrome (LS) include multistep molecular tumor tests to distinguish LS-associated from sporadic colorectal cancer (CRC), which add cost and complexity to the evaluation. We hypothesized...
10.
Guha D, Misra V, Yin J, Horiguchi M, Uno H, Gabuzda D
medRxiv
. 2023 Aug;
PMID: 37546734
Objective: Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) remain prevalent despite viral suppression on antiretroviral therapy (ART). Vascular disease contributes to HAND, but peripheral markers that distinguish vascular cognitive impairment...